CG Oncology initiated with a Buy at TD Cowen

TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology (CGON) with a Buy rating and no price target The firm says cretostimogene is differentiated by its “superior” efficacy and safety to standard of care in BCG-unresponsive, non-muscle invasive bladder cancer, with intravesical administration that is already deployed in practices. TD expects the management team to successfully launch cretostimogene in 2026.